Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
Marije F. Bakker, Guy Cavet, Johannes W. G. Jacobs et al. · Annals of the Rheumatic Diseases · 2012
OBJECTIVES: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. METHODS: Twenty biomarkers were measured in the CAMERA cohort, in which patients were treated with either intensive or conventional methotrexate-based treatment strategies. The MBDA score was calculated using the concentrations of 12 biomarkers (SAA, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40, MMP-3, EGF, VCAM-1, leptin, resistin and CRP) according to a previously trained algorithm. The performance of the scores was evaluated relative to clinical disease activity assessments. Change in MBDA score over time was assessed by paired Wilcoxon rank sum test. Logistic regression was used to evaluate the ability of disease activity measures to predict radiographic progression. RESULTS: The MBDA score had a significant correlation with the disease activity score based on 28 joints-C reactive protein (DAS28-CRP) (r=0.72; p<0.001) and an area under the receiver operating characteristic curve for distinguishing remission/low from moderate/high disease activity of 0.86 (p<0.001) using a DAS28-CRP cut-off of 2.7. In multivariate analysis the MBDA score, but not CRP, was an independent predictor of disease activity measures. Additionally, mean (SD) MBDA score decreased from 53 (18) at baseline to 39 (16) at 6 months in response to study therapy (p<0.0001). Neither MBDA score nor clinical variables were predictive of radiographic progression. CONCLUSIONS: This multi-biomarker test performed well in the assessment of disease activity in RA patients in the CAMERA study. Upon further validation, this test could be used to complement currently available disease activity measures and improve patient care and outcomes.
Cited by 120 works. doi:10.1136/annrheumdis-2011-200963 Open-access PDF
Authors
- Marije F. Bakker
- Guy Cavet
- Johannes W. G. Jacobs
- J. W. J. Bijlsma
- Douglas J. Haney
- Yijing Shen
- Lyndal K. Hesterberg
- Dustin R. Smith
- Michael B Centola
- Joël A. G. van Roon
- Floris P. J. G. Lafeber
- Paco M J Welsing
References
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
- Computer-Aided Multivariate Analysis
- Treating rheumatoid arthritis to target: recommendations of an international task force
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
- Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
- Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values
- Epidemiology and burden of illness of rheumatoid arthritis
- Grading of tenderness as a source of interrater error in the Ritchie articular index.